<?xml version="1.0" encoding="UTF-8"?>



<records>

  <record>
    <language>eng</language>
          <publisher>Oriental Scientific Publishing Company</publisher>
        <journalTitle>Biomedical and Pharmacology Journal</journalTitle>
          <issn>0974-6242</issn>
            <publicationDate>2020-03-28</publicationDate>
    
        <volume>13</volume>
        <issue>1</issue>

 
    <startPage>457</startPage>
    <endPage>468</endPage>

	 
      <doi>10.13005/bpj/1906</doi>
        <publisherRecordId>31300</publisherRecordId>
    <documentType>article</documentType>
    <title language="eng">In Silico Vaccine Design against Mycoplasma Hominis Infections</title>

    <authors>
	 


      <author>
       <name>Shilpa Shiragannavar</name>

 
		
	<affiliationId>1</affiliationId>
      </author>
    

	 


      <author>
       <name>Shivakumar Madagi</name>


		
	<affiliationId>1</affiliationId>

      </author>
    

	

	


	


	
    </authors>
    
	    <affiliationsList>
	    
		
		<affiliationName affiliationId="1">Karnataka State Akkamahadevi Women’s University, Vijayapura</affiliationName>
    

		
		
		
		
		
	  </affiliationsList>






    <abstract language="eng"><em>Mycoplasma hominis</em> is a gram negative bacteria belonging to class Mollicutes, commonly present in men and women of reproductive age. In women it affects the genital tract and is involved in causing Pelvic Inflammatory Disease, ectopic pregnancy, miscarriage, epididymitis in men and sometimes prolonged infection may lead to infertility. At present there is no effective prophylaxis for <em>M.hominis </em>infections<em>.</em> The current work involves <em>insilico</em> reverse vaccinology approach for identifying the immunogens as vaccine candidates that can be effective against reinfections and should be capable of inducing long-term protective immunity against <em>Mycoplasma</em> infections. The study identifies the putative vaccine candidates that are membrane bound with high antigenicity properties which involves identification of T-cell and B-cell epitopes that induce humoral immunity as well as cell-mediated immunity and makes the body stronger against infections and effective for reinfections. The epitope ‘STNYYNLYF’ showed good binding interactions 9.80Kcal/mol with HLA-C*05:01 and maximum population coverage.</abstract>

    <fullTextUrl format="html">https://biomedpharmajournal.org/vol13no1/in-silico-vaccine-design-against-mycoplasma-hominis-infections/</fullTextUrl>

<keywords language="eng">

      
        <keyword>Antigenicity</keyword>
      

      
        <keyword> Docking</keyword>
      

      
        <keyword> In-Silico</keyword>
      

      
        <keyword> Mycoplasma Hominis </keyword>
      

      
        <keyword> Vaccine</keyword>
      
</keywords>
  </record>
</records>